PURPOSE: To obtain an anti-osteoporosis agent having a suppressive function against osteoclast formation and excellent in activity and safety by compounding a polyisoprenoide derivative as an effective component.
CONSTITUTION: This agent contains a compound of formula I (R is OH, formula II or formula III; waved line is an E-type or a Z-type double bond), e.g. (2E,6E,10 E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraene-1-ol. The agent may be formulated into a preparation, e.g. a powder, a particle, a granule, a tablet, a coated tablet, a capsule, an ointment, a plaster or an injection. A daily dose for an adult is 100-3000mg. The compound of formula I has the suppressive activity against osteoclast formation in a coexistent system of an osteoblast and a spleen cell. In osteoporosis, the balance between bone resorption and osteogenesis is destroyed and the bone resorption is accelerated. As a result, the amount of bone is decreased, bones become fragile and pain is accompanied. Osteoporosis frequently occurs especially in a postmenopausal woman and its treatment continues for a long time. Therefore, the danger of the occurrence of side effects characteristic to female sex hormones is concerned and so as drug is required to have high safety.
AKIYAMA YASUHIRO
NAKAMURA TETSUYA
Next Patent: PERCUTANEOUS ABSORPTION TAPE FOR LOCAL ANESTASIA